Skip to main content
Erschienen in: Current Hepatology Reports 2/2017

17.05.2017 | Hepatitis B (J Lim, Section Editor)

Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection

verfasst von: Mohit Mittal, Ke-Qin Hu

Erschienen in: Current Hepatology Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to discuss the clinical implications of occult hepatitis B virus infection (OBI) and management options.

Recent Findings

Data regarding the role of OBI as a co-infection and its ability to facility progression of cirrhosis and hepatocellular carcinoma remain conflicting. In a recent meta-analysis, those with chronic hepatitis C and occult hepatitis B co-infection were found to be at increased risk for development of hepatocellular carcinoma. There remains limited data on how to manage these patients to prevent disease progression.

Summary

OBI refers to the presence of hepatitis B viral (HBV) DNA in serum or hepatocytes in the absence of detectable HBV surface antigen (HBsAg) with or without serological markers of previous exposure. As our understanding of the virology has progressed, so has our understanding of the clinical implications of OBI. Despite the growing evidence of the clinical implications of OBI, there are also several conflicting reports in the literature. After years of research, we have further understanding of the pathogenesis of OBI, but many questions remain unanswered. What we do know is that what was once felt to be a relatively innocuous entity is now regarded as a clinically very relevant disease process requiring appropriate assessment and individualized clinical management.
Literatur
1.
Zurück zum Zitat Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed
2.
Zurück zum Zitat Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefPubMed Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefPubMed
3.
Zurück zum Zitat Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7.CrossRefPubMed Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7.CrossRefPubMed
4.
Zurück zum Zitat Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998;27:1736–42.CrossRefPubMed Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998;27:1736–42.CrossRefPubMed
5.
Zurück zum Zitat Gerlich WH. Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology. 2014;57:202–11.CrossRefPubMed Gerlich WH. Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology. 2014;57:202–11.CrossRefPubMed
6.
Zurück zum Zitat Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion. 2013;53:2449–58.CrossRefPubMed Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion. 2013;53:2449–58.CrossRefPubMed
7.
Zurück zum Zitat Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion. 2013;53:1405–15.CrossRefPubMed Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion. 2013;53:1405–15.CrossRefPubMed
8.
Zurück zum Zitat Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M. HBV transmission from an occult carrier with five mutations the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol. 2013;58:315–7.CrossRefPubMed Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M. HBV transmission from an occult carrier with five mutations the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol. 2013;58:315–7.CrossRefPubMed
9.
Zurück zum Zitat Furuta RA, Kondo Y, Saito T, Tomita M, Oka K, Kishimoto Y. Transfusions of red blood cells from an occult hepatitis B virus carrier without apparent signs of transfusion-transmitted hepatitis B infection. Transfus Med. 2008;18:379–81.CrossRefPubMed Furuta RA, Kondo Y, Saito T, Tomita M, Oka K, Kishimoto Y. Transfusions of red blood cells from an occult hepatitis B virus carrier without apparent signs of transfusion-transmitted hepatitis B infection. Transfus Med. 2008;18:379–81.CrossRefPubMed
10.
Zurück zum Zitat Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS, et al. The clinical significance of occult hepatitis B transfusion in Taiwan—a look-back study. Transfus Med. 2011;21:33–41.CrossRefPubMed Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS, et al. The clinical significance of occult hepatitis B transfusion in Taiwan—a look-back study. Transfus Med. 2011;21:33–41.CrossRefPubMed
12.
Zurück zum Zitat Fontenele AM, Filho NS, Ferreira AS. Occult hepatitis B in patients on hemodialysis: a review. Ann Hepatol. 2013;12:527–31.PubMed Fontenele AM, Filho NS, Ferreira AS. Occult hepatitis B in patients on hemodialysis: a review. Ann Hepatol. 2013;12:527–31.PubMed
13.
Zurück zum Zitat Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40:1072–7.CrossRefPubMed Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40:1072–7.CrossRefPubMed
14.
Zurück zum Zitat Yoo JH, Hwang SG, Yang DH, Son MS, Kwon CI, Ko KH. Prevalence of occult hepatitis B virus infection in hemodialysis patients. Korean J Gastroenterol. 2013;61:209–14.CrossRefPubMed Yoo JH, Hwang SG, Yang DH, Son MS, Kwon CI, Ko KH. Prevalence of occult hepatitis B virus infection in hemodialysis patients. Korean J Gastroenterol. 2013;61:209–14.CrossRefPubMed
15.
Zurück zum Zitat Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol. 2005;20:1641–51.CrossRefPubMed Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol. 2005;20:1641–51.CrossRefPubMed
16.
Zurück zum Zitat Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial. 2008;21:440–6.CrossRefPubMed Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial. 2008;21:440–6.CrossRefPubMed
17.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC). Hepatitis-control measures for hepatitis B in dialysis centers. In: Hepatitis surveillance report no. 41. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, CDC; 1977:12–17. Centers for Disease Control and Prevention (CDC). Hepatitis-control measures for hepatitis B in dialysis centers. In: Hepatitis surveillance report no. 41. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, CDC; 1977:12–17.
18.
Zurück zum Zitat Moyer LA, Alter MJ, Favero MS. Hemodialysis-associated hepatitis B; revised recommendations for serologic screening. Semin Dial. 1990;3:201–4.CrossRef Moyer LA, Alter MJ, Favero MS. Hemodialysis-associated hepatitis B; revised recommendations for serologic screening. Semin Dial. 1990;3:201–4.CrossRef
19.
Zurück zum Zitat Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol. 2013;35:39–52.CrossRefPubMed Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol. 2013;35:39–52.CrossRefPubMed
20.
Zurück zum Zitat Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–6.CrossRefPubMed Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–6.CrossRefPubMed
21.
Zurück zum Zitat Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol. 2006;45:127–43.CrossRefPubMed Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol. 2006;45:127–43.CrossRefPubMed
22.
Zurück zum Zitat Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet. 1994;343:142–6.CrossRefPubMed Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet. 1994;343:142–6.CrossRefPubMed
23.
Zurück zum Zitat Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997;113:1668–74.CrossRefPubMed Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997;113:1668–74.CrossRefPubMed
24.
Zurück zum Zitat Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95:960–5.CrossRefPubMed Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95:960–5.CrossRefPubMed
25.
Zurück zum Zitat Song ZL, Chi YJ, Zhen WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol. 2015;21:12091–100.CrossRefPubMedPubMedCentral Song ZL, Chi YJ, Zhen WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol. 2015;21:12091–100.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Kwon CI, Hwang SG, Shin SJ, Chang SW, Kim SY, Ko KH, et al. Occult hepatitis B virus infection in pregnant woman and its clinical implication. Liver Int. 2008;28:667–74.CrossRefPubMed Kwon CI, Hwang SG, Shin SJ, Chang SW, Kim SY, Ko KH, et al. Occult hepatitis B virus infection in pregnant woman and its clinical implication. Liver Int. 2008;28:667–74.CrossRefPubMed
27.
Zurück zum Zitat Maldonado-Rodriguez A, Cevallos AM, Rojas-Montes O, Enriquez-Navarro K, Alvarez-Muñoz MT, Lira R. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: a review of prevalence, diagnosis and clinical significance. World J Hepatol. 2015;7:253–60.CrossRefPubMedPubMedCentral Maldonado-Rodriguez A, Cevallos AM, Rojas-Montes O, Enriquez-Navarro K, Alvarez-Muñoz MT, Lira R. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: a review of prevalence, diagnosis and clinical significance. World J Hepatol. 2015;7:253–60.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60.CrossRefPubMed Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60.CrossRefPubMed
29.
Zurück zum Zitat • Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol. 2014;6:384–93. Important review about immunosuppressed patients with occult hepatitis B infection. • Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol. 2014;6:384–93. Important review about immunosuppressed patients with occult hepatitis B infection.
30.
Zurück zum Zitat Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, et al. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015;21:11931–40.CrossRefPubMedPubMedCentral Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, et al. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015;21:11931–40.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013;59:696–700.CrossRefPubMed Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013;59:696–700.CrossRefPubMed
32.
Zurück zum Zitat Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80:1547–53.CrossRefPubMed Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80:1547–53.CrossRefPubMed
33.
Zurück zum Zitat Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45:238–44. Recent meta-analysis of risk for progression to cirrhosis in those with occult hepatitis B. CrossRefPubMed Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45:238–44. Recent meta-analysis of risk for progression to cirrhosis in those with occult hepatitis B. CrossRefPubMed
34.
Zurück zum Zitat •• Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126(1):102–10. •• Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126(1):102–10.
35.
Zurück zum Zitat Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106:1326–30.CrossRefPubMed Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106:1326–30.CrossRefPubMed
36.
Zurück zum Zitat Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, et al. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology. 2008;51:59–68.CrossRefPubMed Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, et al. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology. 2008;51:59–68.CrossRefPubMed
37.
Zurück zum Zitat Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14:534–40.CrossRefPubMed Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14:534–40.CrossRefPubMed
38.
Zurück zum Zitat Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54:434–42.CrossRefPubMedPubMedCentral Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54:434–42.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat •• Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231–40. Recent meta-analysis of risk of development of HCC in those with occult hepatitis B. •• Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231–40. Recent meta-analysis of risk of development of HCC in those with occult hepatitis B.
40.
Zurück zum Zitat Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351:317–20.CrossRefPubMed Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351:317–20.CrossRefPubMed
41.
Zurück zum Zitat Tamori A, Yamanishi Y, Kawashima S, Kanehisa M, Enomoto M, Tanaka H, et al. Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Cancer Res. 2005;11:5821–6.CrossRefPubMed Tamori A, Yamanishi Y, Kawashima S, Kanehisa M, Enomoto M, Tanaka H, et al. Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Cancer Res. 2005;11:5821–6.CrossRefPubMed
42.
Zurück zum Zitat Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogeneis. 2011;32:1122–32.CrossRef Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogeneis. 2011;32:1122–32.CrossRef
44.
Zurück zum Zitat Fallot G, Neuveut C, Buendia MA. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol. 2012;2:467–73.CrossRefPubMed Fallot G, Neuveut C, Buendia MA. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol. 2012;2:467–73.CrossRefPubMed
45.
46.
Zurück zum Zitat Matsuoka S, Nirei K, Tamura A, Nakamura H, Matsumura H, Oshiro S, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology. 2008;51:352–61.CrossRefPubMed Matsuoka S, Nirei K, Tamura A, Nakamura H, Matsumura H, Oshiro S, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology. 2008;51:352–61.CrossRefPubMed
47.
Zurück zum Zitat Arababadi MK, Nasiri Ahmadabadi B, Kennedy D. Current information on the immunologic status of occult hepatitis B infection. Transfusion. 2012;52:1819–26.CrossRefPubMed Arababadi MK, Nasiri Ahmadabadi B, Kennedy D. Current information on the immunologic status of occult hepatitis B infection. Transfusion. 2012;52:1819–26.CrossRefPubMed
48.
Zurück zum Zitat Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–8.CrossRefPubMed Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–8.CrossRefPubMed
49.
Zurück zum Zitat Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54:829–36.CrossRefPubMed Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54:829–36.CrossRefPubMed
50.
Zurück zum Zitat Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006;45:553–9.CrossRefPubMed Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006;45:553–9.CrossRefPubMed
51.
Zurück zum Zitat Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 1995;21:313–21.PubMed Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 1995;21:313–21.PubMed
52.
Zurück zum Zitat Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, Lagorce D, et al. Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging. Oncogene. 2001;20:6233–40.CrossRefPubMed Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, Lagorce D, et al. Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging. Oncogene. 2001;20:6233–40.CrossRefPubMed
53.
Zurück zum Zitat Bläckberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol. 2000;33:992–7.CrossRefPubMed Bläckberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol. 2000;33:992–7.CrossRefPubMed
54.
Zurück zum Zitat Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172–9.CrossRefPubMed Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172–9.CrossRefPubMed
56.
Zurück zum Zitat Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagie JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.CrossRefPubMedPubMedCentral Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagie JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233–40.CrossRefPubMed Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233–40.CrossRefPubMed
58.
Zurück zum Zitat Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.CrossRefPubMed Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.CrossRefPubMed
59.
Zurück zum Zitat Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol. 1999;94:249–51.CrossRefPubMed Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol. 1999;94:249–51.CrossRefPubMed
60.
Zurück zum Zitat Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004;12:191–6.CrossRefPubMed Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004;12:191–6.CrossRefPubMed
61.
Zurück zum Zitat Leaw SJ, Yen CJ, Huang WT, Chen TY, Su CW, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83:270–5.CrossRefPubMed Leaw SJ, Yen CJ, Huang WT, Chen TY, Su CW, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83:270–5.CrossRefPubMed
62.
Zurück zum Zitat Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004;99:2369–75.CrossRefPubMed Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004;99:2369–75.CrossRefPubMed
63.
Zurück zum Zitat Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.CrossRefPubMed Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.CrossRefPubMed
64.
Zurück zum Zitat Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88:209–15.CrossRefPubMed Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88:209–15.CrossRefPubMed
65.
Zurück zum Zitat Li YH, He YF, Jiang WQ, Wang FH, Lin HX, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320–5.CrossRefPubMed Li YH, He YF, Jiang WQ, Wang FH, Lin HX, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320–5.CrossRefPubMed
66.
Zurück zum Zitat Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003–16.CrossRefPubMed Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003–16.CrossRefPubMed
67.
Zurück zum Zitat Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–34.CrossRefPubMed Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–34.CrossRefPubMed
68.
Zurück zum Zitat Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007;46:1049–56.CrossRefPubMed Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007;46:1049–56.CrossRefPubMed
69.
Zurück zum Zitat Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–53.CrossRefPubMed Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–53.CrossRefPubMed
70.
Zurück zum Zitat Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J. 2004;5:325–8.CrossRefPubMed Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J. 2004;5:325–8.CrossRefPubMed
71.
Zurück zum Zitat Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17:3881–7.CrossRefPubMedPubMedCentral Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17:3881–7.CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.CrossRefPubMed Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.CrossRefPubMed
73.
Zurück zum Zitat Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.CrossRefPubMed Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.CrossRefPubMed
74.
Zurück zum Zitat Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909–16.CrossRefPubMed Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909–16.CrossRefPubMed
75.
Zurück zum Zitat Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.CrossRefPubMed Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.CrossRefPubMed
76.
Zurück zum Zitat Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.CrossRefPubMed Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.CrossRefPubMed
77.
Zurück zum Zitat Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.CrossRefPubMed Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.CrossRefPubMed
78.
Zurück zum Zitat Ustün C, Koç H, Karayalcin S, Akyol G, Gürman G, Ilhan O, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:289–96.CrossRefPubMed Ustün C, Koç H, Karayalcin S, Akyol G, Gürman G, Ilhan O, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:289–96.CrossRefPubMed
79.
Zurück zum Zitat Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30.CrossRefPubMed Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30.CrossRefPubMed
80.
Zurück zum Zitat Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003;44:1281–5.CrossRefPubMed Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003;44:1281–5.CrossRefPubMed
81.
Zurück zum Zitat Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:925–9.CrossRefPubMed Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:925–9.CrossRefPubMed
82.
Zurück zum Zitat Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42:813–9.CrossRefPubMed Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42:813–9.CrossRefPubMed
83.
Zurück zum Zitat Michel M, Duvoux C, Hezode C, Cherqui D. Hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol. 2003;30:1624–5.PubMed Michel M, Duvoux C, Hezode C, Cherqui D. Hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol. 2003;30:1624–5.PubMed
84.
Zurück zum Zitat Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686–7.CrossRefPubMedPubMedCentral Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686–7.CrossRefPubMedPubMedCentral
85.
Zurück zum Zitat Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118–21.PubMed Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118–21.PubMed
86.
Zurück zum Zitat Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31:931–6.CrossRefPubMed Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31:931–6.CrossRefPubMed
87.
Zurück zum Zitat Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, BIOGEAS Study Group, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–71.CrossRef Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, BIOGEAS Study Group, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–71.CrossRef
88.
Zurück zum Zitat Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014;27:15–9.PubMedPubMedCentral Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014;27:15–9.PubMedPubMedCentral
89.
Zurück zum Zitat Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab based regimens: a serious complication in both HBsAg positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62.CrossRefPubMed Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab based regimens: a serious complication in both HBsAg positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62.CrossRefPubMed
90.
Zurück zum Zitat European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef
91.
92.
Zurück zum Zitat Abramson JS, Chung RT. Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. JAMA. 2014;312:2505–7.CrossRefPubMed Abramson JS, Chung RT. Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. JAMA. 2014;312:2505–7.CrossRefPubMed
93.
Zurück zum Zitat Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol. 2010;16:5447–51.CrossRefPubMedPubMedCentral Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol. 2010;16:5447–51.CrossRefPubMedPubMedCentral
94.
Zurück zum Zitat Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol. 2009;51:824–5.CrossRefPubMed Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol. 2009;51:824–5.CrossRefPubMed
Metadaten
Titel
Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection
verfasst von
Mohit Mittal
Ke-Qin Hu
Publikationsdatum
17.05.2017
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 2/2017
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0339-9

Weitere Artikel der Ausgabe 2/2017

Current Hepatology Reports 2/2017 Zur Ausgabe

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Autoimmune Hepatitis: When Is It Safe to Stop Therapy, or Withhold Therapy Altogether?

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

Hepatitis B (J Lim, Section Editor)

Management of Chronic Hepatitis B in Children

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.